<DOC>
	<DOCNO>NCT01853982</DOCNO>
	<brief_summary>This Phase 3 , multicenter , prospective , randomize , open-label , study compare safety efficacy intravenous ( IV ) ceftolozane/tazobactam IV piperacillin/tazobactam treatment ventilator-associated pneumonia ( VAP ) adult participant .</brief_summary>
	<brief_title>Study Intravenous Ceftolozane/Tazobactam Compared Piperacillin/Tazobactam Ventilator-Associated Pneumonia</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Ventilator-Associated</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<mesh_term>Ceftolozane , tazobactam drug combination</mesh_term>
	<mesh_term>Piperacillin , tazobactam drug combination</mesh_term>
	<criteria>Key Participant receive mechanical ventilation &gt; 48 hour Acute Physiology Chronic Health Evaluation ( APACHE ) II score 1135 Presence new progressive infiltrate chest xray Presence clinical criterion consistent VAP Key History moderate severe hypersensitivity reaction betalactam antibiotic Known end stage renal disease requirement dialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>